Friday, March 17, 2023
Evotec announced progress within the Company’s strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline.
Evotec and Bristol Myers Squibb entered into strategic protein degradation partnership in 2018 and expanded it in May of 2022, because of the highly productive initial collaboration generating a promising pipeline. The partnership continues to build a leading pipeline of novel molecular glue degraders, targeting high-value targets in the field of oncology and beyond.
This strategic alliance is to discover and develop a leading pipeline of molecular glue degraders for a range of therapeutic indications leveraging all of Evotec’s proprietary PanOmics and PanHunter platforms as well as A.I./M.L.-based drug discovery and development capabilities.
The extension and expansion of partnership with BMS continues to deliver high value programmes. The Omics-based, highly systematic, and industrialised approach to identify very promising molecular glues continually exceeds all expectations and will translate into an extraordinary pipeline of first-in-class product opportunities.
